Compass Therapeutics, Inc. Common Stock
Here’s whether Compass Therapeutics, Inc. Common Stock (CMPX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-10.21% over 10 days); RSI 26 — oversold; 3-month momentum negative (-69.9%); rising volume on a downtrend (distribution, 2.45x avg). Currently 71.5% off its 52-week high. Score: -6/7.
CMPX is trading below its 200-day MA ($4.61) — a key warning sign the longer-term trend is under pressure. An RSI of 26.0 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of +7.7% compares to +22.9% for SPY (trailed the market by 15.2%). The current 71.5% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.